Association between TNF-α & IL-6 level changes and remission from depression with duloxetine treatment.

IF 1.7 4区医学 Q4 NEUROSCIENCES International Journal of Neuroscience Pub Date : 2024-10-18 DOI:10.1080/00207454.2024.2414279

Eriko Suzuki, Akitsugu Sueki, Hitoshi Takahashi, Jun Ishigooka, Katsuji Nishimura

{"title":"Association between TNF-α & IL-6 level changes and remission from depression with duloxetine treatment.","authors":"Eriko Suzuki, Akitsugu Sueki, Hitoshi Takahashi, Jun Ishigooka, Katsuji Nishimura","doi":"10.1080/00207454.2024.2414279","DOIUrl":null,"url":null,"abstract":"Purpose/aim of the study: The pathophysiology of major depressive disorder (MDD) involves multiple factors, including inflammatory processes. This study investigated the relationship between changes in the levels of cytokines and remission in patients with MDD following duloxetine treatment.Materials and methods: MDD patients were administered duloxetine for 16 weeks. Clinical evaluation and immunological monitoring were performed every 4 weeks.Results: Our results indicated that changes in serum levels of TNF-α and IL-6 were associated with remission following duloxetine treatment in MDD patients. There was a slight increase in TNF-α levels in the first four weeks following duloxetine treatment, which correlated significantly with patients who were in remission. Furthermore, patients in remission exhibited an initial increase in IL-6 levels in the first four weeks, followed by a decrease at 16 weeks.Conclusions: These results suggest an important relationship between changes in cytokine levels and remission in patients with major depression after duloxetine treatment.","PeriodicalId":14161,"journal":{"name":"International Journal of Neuroscience","volume":" ","pages":"1-6"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00207454.2024.2414279","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose/aim of the study: The pathophysiology of major depressive disorder (MDD) involves multiple factors, including inflammatory processes. This study investigated the relationship between changes in the levels of cytokines and remission in patients with MDD following duloxetine treatment.

Materials and methods: MDD patients were administered duloxetine for 16 weeks. Clinical evaluation and immunological monitoring were performed every 4 weeks.

Results: Our results indicated that changes in serum levels of TNF-α and IL-6 were associated with remission following duloxetine treatment in MDD patients. There was a slight increase in TNF-α levels in the first four weeks following duloxetine treatment, which correlated significantly with patients who were in remission. Furthermore, patients in remission exhibited an initial increase in IL-6 levels in the first four weeks, followed by a decrease at 16 weeks.

Conclusions: These results suggest an important relationship between changes in cytokine levels and remission in patients with major depression after duloxetine treatment.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

TNF-α和IL-6水平变化与度洛西汀治疗抑郁症缓解之间的关系

研究目的/目标：重度抑郁障碍（MDD）的病理生理学涉及多种因素，包括炎症过程。本研究调查了度洛西汀治疗后，细胞因子水平的变化与重度抑郁症患者病情缓解之间的关系：多发性硬化症患者接受为期 16 周的度洛西汀治疗。每4周进行一次临床评估和免疫学监测：结果：我们的研究结果表明，MDD患者接受度洛西汀治疗后，血清中TNF-α和IL-6水平的变化与病情缓解有关。在度洛西汀治疗后的前四周，TNF-α水平略有上升，这与缓解期患者有显著相关性。此外，缓解期患者的IL-6水平在前四周开始升高，16周后有所下降。结论这些结果表明，在接受度洛西汀治疗后，细胞因子水平的变化与重度抑郁症患者的病情缓解之间存在重要关系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Neuroscience 医学-神经科学

CiteScore

5.10

自引率

0.00%

发文量

132

审稿时长

2 months

期刊介绍： The International Journal of Neuroscience publishes original research articles, reviews, brief scientific reports, case studies, letters to the editor and book reviews concerned with problems of the nervous system and related clinical studies, epidemiology, neuropathology, medical and surgical treatment options and outcomes, neuropsychology and other topics related to the research and care of persons with neurologic disorders. The focus of the journal is clinical and transitional research. Topics covered include but are not limited to: ALS, ataxia, autism, brain tumors, child neurology, demyelinating diseases, epilepsy, genetics, headache, lysosomal storage disease, mitochondrial dysfunction, movement disorders, multiple sclerosis, myopathy, neurodegenerative diseases, neuromuscular disorders, neuropharmacology, neuropsychiatry, neuropsychology, pain, sleep disorders, stroke, and other areas related to the neurosciences.